Univariate analysis of relationship between m-MDSC and OS at pretreatment baseline and week 6 after ipilimumab
Ipilimumab treated | ||||||
---|---|---|---|---|---|---|
Pretreatment | Week 6 | |||||
n | HR (95% CI) | P | n | HR (95% CI) | P | |
MDSC < 14.9% | 68 | 0.35 (0.18–0.70) | 0.002 | 64 | 0.38 (0.19–0.75) | 0.004 |
ALC ≥ 1,000 cells/μL | 68 | 0.73 (0.41–1.33) | 0.303 | 64 | 0.22 (0.11–0.45) | <0.001 |
LDH < 250 | 68 | 0.33 (0.18–0.59) | <0.001 | 65 | 0.37 (0.20–0.68) | 0.001 |
Monocytes < 300 cells/μL | 68 | 0.70 (0.25–1.95) | 0.495 | 64 | 1.77 (0.69–4.51) | 0.233 |